Phase II study of topotecan in metastatic hormone-refractory prostate cancer

  title={Phase II study of topotecan in metastatic hormone-refractory prostate cancer},
  author={Gary R. Hudes and Richard Kosierowski and Richard Greenberg and Harry E. Ramsey and Stephen C. Fox and Robert F. Ozols and Cecilia A. McAleer and Bruce J. Giantonio},
  journal={Investigational New Drugs},
Systemic chemotherapy with currently available agents has not improved survival for patients with hormone refractory prostate cancer (HRPC), consequently, the evaluation of new agents is warranted. Topotecan is a specific inhibitor of topoisomerase I with broad antitumor activity in preclinical studies. The purpose of this phase II trial was to determine the objective response rate of topotecan administered as a 30 minute infusion for five consecutive days in men with metastatic HRPC. Thirty… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 25 references

Bioavailability of oral topotecan, a new topoisomerase I inhibitor

  • G JCreemers, JH Schellens, +8 authors J Verweij
  • Proceedings of ASCO 13:132,
  • 1994
1 Excerpt

LE: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

  • KJ Pienta, B Redman, +4 authors Flaherty
  • J Clin Oncol 12:20052012,
  • 1994
1 Excerpt

The current status of camptothecin analogs as antitumor agents

  • WJ Slichenmeyer, EK Rowinsky, RC Donehower, SH Kaufmann
  • J Natl Cancer Inst 85:271-291,
  • 1993
1 Excerpt

Similar Papers

Loading similar papers…